MissionIR Articles
Original content written and distributed as part of our ongoing relationships.
-
The Shares of Nutrition 21, Inc. (NasdaqCM: NXXI) were Up Sharply Tuesday 5.13%; as the Company is Set to Present at the RedChip Small Cap Conference
Nutrition 21, Inc. is Set to Present at the RedChip Small Cap Conference Next Month in New York City. The Company is involved in research and product development aimed to help diabetics. Recently, Nutrition 21,…
-
MRV Communications (MRVC) Shares Plunge after News of Closing
Share prices for MRV Communications (NASDAQ: MRVC) tumbled more than 13 percent this morning after the company announced along with its subsidiary, Luminent Inc., has closed on its previously acquired company Fiberxon.According to the press…
-
Optibase (OBAS) Overhauls Airport Communications
Optibase Ltd. (NASDAQ: OBAS) proved itself an up-and-coming contender in the video solutions industry last week after it announced its latest multi-platform project at Vancouver International Airport in Vancouver, Canada.According to the press release, the…
-
VistaGen’s (VSTA) AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications
VistaGen Therapeutics, Inc., an emerging biopharmaceutical company, focused on stem cell technologies, to discover, develop and commercialize novel small molecule drugs and protein therapeutics for neurological disorders and diabetes, announced positive results from preclinical studies…
-
VistaGen Therapeutics (VSTA) Announces 3 Significant Publications Supporting the Use of Embryonic Stem Cells for Drug Discovery and Development
VistaGen Therapeutics Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and neurological diseases, announced today three…
-
VistaGen Therapeutics (VSTA) Announces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson’s Disease
VistaGen Therapeutics, Inc., a biopharmaceutical company developing drugs for treating neurological disorders and diabetes, announced today positive preclinical data supporting expanded applications of AV-101, the Company’s first in-class prodrug that regulates critical NMDA receptors in…
-
VistaGen Therapeutics (VSTA) and Sanwa Renew Embryonic Stem Cell Drug Discovery and Development Partnership Focused on New Diabetes Treatments
VistaGen Therapeutics, Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and central nervous system disorders, announced…
-
VistaGen Therapeutics (VSTA) and CATO BioVentures Sign Strategic Business Development Agreement for CNS Products
VistaGen Therapeutics Inc., a biopharmaceutical company applying leading embryonic stem cell technology to discover and develop novel treatments for central nervous system disorders, diabetes and cardiovascular disease, and Cato BioVentures, the venture capital affiliate of…
-
Lantos Affirms Support of Expanded Stem Cell Research — Applauds Commitment by VistaGen Employees and Investors
Congressman Tom Lantos (D-San Francisco, San Mateo) speaking from the laboratories of VistaGen Therapeutics, a biopharmaceutical company, affirmed his support of the expansion of stem cell research using human embryos that would otherwise become medical…
-
VistaGen Therapeutics Secures Development Support for New Drug Candidate forHuntington’s Disease
VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics using embryonic stem cell technologies, announced today that the High Q Foundation, Inc. has agreed…
-
VistaGen Therapeutics (VSTA) Awarded $197,000 NIH Grant for Expanded PreclinicalDevelopment of New Drug Candidate for Neuropathic Pain
VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) and Peripheral Nervous System (PNS) disorders and metabolic diseases using…
-
VistaGen Therapeutics (VSTA) Awarded $3,700,000 NIH Drug Development Grant for LeadEpilepsy Drug Candidate
Burlingame, CA, May 24, 2005 /PRNewswire/ — VistaGen Therapeutics, Inc., a development stage biopharmaceutical company focused on discovering, developing and commercializing novel small molecule and protein therapeutics for Central Nervous System (CNS) disorders and metabolic…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Hits $100 Million in Transaction Volume for Licensed Coin-In/Coin-Out Services
- MissionIRNewsBreaks – Wearable Devices Ltd. (NASDAQ: WLDS, WLDSW) Secures U.S. Patent for Gesture and Voice-Controlled Neural Interface
- MissionIRNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Steps Aside Temporarily to Run for Irish Presidency
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Q2 2025 Results and Business Highlights